SCREENING FOR PROSTATE CANCER APPEARS TO WORK, BUT AT WHAT COST?

被引：4
|
作者：
Parker, Chris [2 ]
Emberton, Mark [1 ]
机构：
[1] UCL, UCLH, Comprehens Biomed Ctr, Div Surg & Intervent Sci, London WC2 3PU, England
[2] Royal Marsden Hosp, Acad Urol Unit, Inst Canc Res, Sutton, Surrey, England
来源：
BJU INTERNATIONAL | 2009年 / 104卷 / 03期
基金：
英国医学研究理事会;
关键词：
MORTALITY; RISK;
D O I：
10.1111/j.1464-410X.2009.08689.x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：290 / 292
页数：3
相关论文
共 50 条
  • [41] Screening for prostate cancer is neither appropriate nor cost-effective
    Albertsen, PC
    UROLOGIC CLINICS OF NORTH AMERICA, 1996, 23 (04) : 521 - +
  • [42] COST-EFFECTIVENESS OF PROSTATE-CANCER SCREENING AND TREATMENT - RESPONSE
    GARNICK, MB
    ANNALS OF INTERNAL MEDICINE, 1993, 119 (10) : 1055 - 1055
  • [43] Cost effectiveness analysis of screening in the early diagnosis of prostate cancer (IPCA)
    Mueller-Lisse, UG
    Mueller-Lisse, UL
    RADIOLOGE, 2002, 42 (08): : 601 - 607
  • [44] INTEGRATING NOVEL SCREENING METHODS FOR PROSTATE CANCER, COST UTILITY INTERVENTIONS
    Dragomir, A.
    Bonnevier, E.
    Kassouf, W.
    Aprikian, A.
    Palenius, E.
    Nazha, S.
    VALUE IN HEALTH, 2017, 20 (09) : A589 - A589
  • [45] Screening for chlamydia: what is the cost?
    Pozniak, AL
    CURRENT OPINION IN INFECTIOUS DISEASES, 2005, 18 (01) : 35 - 36
  • [46] Prostatakrebsscreening – wo stehen wir?Prostate cancer screening – what is the situation?
    P. Hammerer
    Forum, 2015, 30 (1) : 46 - 50
  • [47] What's the best approach for screening asymptomatic men for prostate cancer?
    Holten, Keith B.
    Al-Abdulla, Sally
    JOURNAL OF FAMILY PRACTICE, 2009, 58 (12): : E4 - E6
  • [48] Impact of improvement in specificity of primary screening test on total cost of prostate cancer mass screening
    Kobayashi, Takashi
    Goto, Rei
    Fukui, Tsuguya
    Ogawa, Osamu
    INTERNATIONAL JOURNAL OF UROLOGY, 2007, 14 (09) : 805 - 810
  • [49] HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico
    Flores, Yvonne N.
    Bishai, David M.
    Lorincz, Attila
    Shah, Keerti V.
    Lazcano-Ponce, Eduardo
    Hernandez, Mauricio
    Granados-Garcia, Victor
    Perez, Ruth
    Salmeron, Jorge
    CANCER CAUSES & CONTROL, 2011, 22 (02) : 261 - 272
  • [50] Prostate-Specific Antigen, Prostate Cancer Screening, and the Pathologist What Should Be Our Role?
    Jackson, Brian R.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2013, 137 (03) : 308 - 309
12345